Status:
COMPLETED
Prospective Study of the Evaluation of Disease contRol and the Quality of Life of Patients With depressiOn and With or Without aNxiety disOrders in the Greek populatIon
Lead Sponsor:
Elpen Pharmaceutical Co. Inc.
Conditions:
Depression
Anxiety Disorders
Eligibility:
All Genders
18-80 years
Brief Summary
Depression is a psychiatric disorder that affects mood, thoughts and is usually accompanied by physical annoyances. It affects the person's eating habits, his sleep, the way he sees himself and the wa...
Detailed Description
The Hamilton Depression Scale is the most widely used scale for measuring the severity of depression worldwide. It was designed to measure the severity of depression in already diagnosed patients with...
Eligibility Criteria
Inclusion
- Signed informed consent form
- Male or female asthma patients over 18 years of age
- Compliance with treatment
- Compliance with study procedures
- Patients already receiving or to receive citalopram
- Patients not adequately controlled by citalopram
- Patients not adequately controlled by citalopram and at the same time having a generalized anxiety disorder
- Patients not regulated at all
Exclusion
- Unsigned patient consent
- Male or female asthma patients under 18 years of age
- Non-compliance with treatment
- Non-compliance in study procedures
- Patients who do not meet the Product SmPC criteria
- Patients receiving MAO inhibitors
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2019
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT03317262
Start Date
March 1 2018
End Date
March 1 2019
Last Update
May 13 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Private Office
Larissa, Greece